quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:56:48·72d
ANALYSTRating
Passage Bio Inc. logo

Chardan Capital Markets resumed coverage on Passage BIO with a new price target

PASG· Passage Bio Inc.
Health Care
Original source

Companies

  • PASG
    Passage Bio Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateTD Cowen-
  • Apr 21UpdateChardan Capital Markets$7.00
  • Apr 21UpdateWedbush$8.00
  • Mar 31UpdateOppenheimer$30.00
  • Feb 10UpdateChardan Capital Markets$21.00
  • Nov 29UpdateWedbush$4.00

Related

  • ANALYST2d
    Passage BIO downgraded by TD Cowen
  • ANALYST2d
    Passage BIO downgraded by Chardan Capital Markets with a new price target
  • ANALYST2d
    Passage BIO downgraded by Wedbush with a new price target
  • SEC3d
    Passage Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR3d
    Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
  • SEC16d
    SEC Form DEFA14A filed by Passage Bio Inc.
  • SEC16d
    SEC Form DEF 14A filed by Passage Bio Inc.
  • ANALYST23d
    Oppenheimer initiated coverage on Passage BIO with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022